ArticleDiscover oncology2026
Ginsenoside Rg1 triggers ferroptosis to inhibit hepatocellular carcinoma via SLC7A11 downregulation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ginsenoside Rg1 (Rg1) has been reported to exert its adjunctive antitumor efficacy in cancer therapy, including hepatocellular carcinoma (HCC). Here, our study revealed the role of Rg1 on HCC involving ferroptosis. Functionally, Rg1 significantly inhibited the proliferation and migration ability of HCC cells, demonstrating its anti-HCC effect. In addition, Rg1 could induce the ferroptosis-related characteristics of HCC, thereby triggering ferroptosis. Mechanistically, SLC7A11 was identified as a potential downstream mediator of Rg1, and further studies are required to validate its functional role, and Rg1 inhibited the expression of SLC7A11. This downregulation of SLC7A11 by Rg1 recovered the ferroptosis sensitivity, thereby activating ferroptosis and contributing to HCC treatment. In conclusion, our findings unveil a link between Rg1 and ferroptosis, supporting a therapeutic strategy to overcome HCC by targeting ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.